Latest News

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.

SAR448851 showed favorable safety, high CNS penetration, and up to 50% reductions in CSF soluble TREM2 in phase 1, supporting the design of TREMHANCE, a phase 2 trial now in final planning with p-tau217 as its primary endpoint.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 17, 2026.

The global phase 3 registration trial enrolled 1535 patients across 240 sites and has completed its 52-week double-blind treatment phase, with no unexpected safety signals observed, even in participants on concomitant antiamyloid therapies.

A cross-sectional survey of 4181 NARCOMS Registry participants found that only 7.4% had ever used semaglutide or tirzepatide, despite 40% meeting FDA-approved indications for the drugs.

Across 3 first-in-human studies in healthy volunteers and cognitively impaired adults, MK-2214 demonstrated dose-proportional pharmacokinetics, an approximately 80-day half-life, and near-complete suppression of free pS413 tau in CSF at doses of 20 mg and above.

Arif Dalvi, MD, director of the Comprehensive Movement Disorders Center at Palm Beach Health Network in Florida, discusses new Lancet Neurology data on staged bilateral focused ultrasound for Parkinson disease motor complications.

If approved, AD109 could become the first medication to address both the nighttime airway obstruction and oxygen deprivation central to OSA, as well as its daytime symptoms, such as fatigue.

The FDA files the NDA for Axsome’s AXS-12 for cataplexy in narcolepsy, backed by phase 3 data wins showing fewer attacks and better daytime alertness.

The 60 mg dose showed the largest treatment effect, slowing decline by 26% on CDR-SB, 42% on ADAS-Cog13, and 50% on MMSE at 18 months, while all doses produced 50% to 65% reductions in CSF total tau and unprecedented tau PET reductions across brain regions.

MCLENA-1 enrolled only 6 completers due to funding constraints but demonstrated 12 months of continuous lenalidomide was safe and tolerable, with nonsignificant trends favoring treatment on cognition and global outcomes.

In a single-center retrospective analysis, approximately two-thirds of patients with treatment-refractory headache disorders reported improvement with off-label suzetrigine, supporting further prospective evaluation of the selective NaV1.8 inhibitor.

A new phase 2 trial, presented at AAIC 2026, aims to evaluate the effects of urolithin A on mitophagy/autophagy activity, oxidative stress, multi-omic profiling, and cognitive function in APOE4 carriers.